Literature DB >> 24013121

Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.

Liusheng Huang1, Patricia Lizak, Francesca Aweeka, Janel Long-Boyle.   

Abstract

Fludarabine is a nucleoside analog routinely used in conditioning regimens of pediatric allogeneic stem cell transplantation to promote stem cell engraftment. In children, it remains a challenge to accurately and precisely quantify the active intracellular triphosphate species of fludarabine in vivo, primarily due to limitations on blood volume and inadequate assay sensitivity. Here we report a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for determination of fludarabine triphosphate in human peripheral blood mononuclear cells (PBMC). PBMC (∼5 million cells) were collected and lysed in 1mL 70% methanol containing 1.2mM tris buffer (pH 7.4). The lysate (80μL) was mixed with internal standard (2-chloro-adenosine triphosphate, 150ng/mL, 20μL) and injected onto an API5000 LC-MS/MS system. Separation was achieved on a hypercarb column (100mm×2.1mm, 3μm) eluted with 100mM ammonium acetate (pH 9.8) and acetonitrile in a gradient mode at a flow rate of 0.4mL/min. Multiple reactions monitoring (MRM) and electrospray ionization in negative mode (ESI(-)) were used for detection. The ion pairs 524.0/158.6 for the drug and 540.0/158.8 for the IS were selected for quantification and 524.0/425.7 used for confirmation. Retention time was 3.0 and 3.4min for fludarabine triphosphate and the IS, respectively. The concentration range for the calibration curve was 1.52-76nM. Our method is simple, fast, and has been successfully applied in a clinical dose-concentration study in children to quantify intracellular fludarabine in low volume clinical samples. The median concentration was 1.03 and 3.19pmole/million PBMC at trough and peak time points, respectively. Fludarabine triphosphate is degraded in water within hours but relatively stable in 70% methanol-tris (1.2mM, pH 7.4). One limitation is that the hypercarb column takes a longer time to equilibrate than conventional reverse phase columns, and peaks become broad and distorted if the column is not washed and stored properly.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2-chloroadenosine triphosphate; Cl-ara-ATP; F-ara-ATP; Fludarabine triphosphate; Hypercarb column; LC–MS/MS; PBMC; PK; Stability; alloHCT; allogeneic hematopoietic cell transplantation; fludarabine triphosphate; peripheral blood mononuclear cells; pharmacokinetic

Mesh:

Substances:

Year:  2013        PMID: 24013121      PMCID: PMC3835489          DOI: 10.1016/j.jpba.2013.08.007

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  30 in total

Review 1.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

2.  Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia.

Authors:  Franklin O Smith; Roberta King; Gene Nelson; John E Wagner; Kent A Robertson; Jean E Sanders; Nancy Bunin; Peter D Emaunel; Stella M Davies
Journal:  Br J Haematol       Date:  2002-03       Impact factor: 6.998

3.  Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

4.  Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.

Authors:  L Malspeis; M R Grever; A E Staubus; D Young
Journal:  Semin Oncol       Date:  1990-10       Impact factor: 4.929

5.  Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).

Authors:  L Grigull; A Beilken; M Schrappe; A Das; T Luecke; A Sander; M Stanulla; K Rehe; M Sauer; H Schmid; K Welte; Z Lukacs; A Gal; K W Sykora
Journal:  Bone Marrow Transplant       Date:  2005-02       Impact factor: 5.483

6.  Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia.

Authors:  Michael R Verneris; Mary Eapen; Reggie Duerst; Paul A Carpenter; Michael J Burke; B V Afanasyev; Morton J Cowan; Wensheng He; Robert Krance; Chi-Kong Li; Poh-Lin Tan; John E Wagner; Stella M Davies
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-17       Impact factor: 5.742

7.  Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry.

Authors:  François Becher; Alain Pruvost; Cécile Goujard; Catherine Guerreiro; J-F Delfraissy; Jacques Grassi; Henri Benech
Journal:  Rapid Commun Mass Spectrom       Date:  2002       Impact factor: 2.419

8.  Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival.

Authors:  Eliane Gluckman; Vanderson Rocha; Irina Ionescu; Marc Bierings; Richard E Harris; John Wagner; Joanne Kurtzberg; Martin A Champagne; Carmem Bonfim; Marco Bittencourt; Philip Darbyshire; Manuél-Nicolas Fernandez; Franco Locatelli; Ricardo Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-20       Impact factor: 5.742

9.  A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.

Authors:  Erica L Woodahl; Joanne Wang; Shelly Heimfeld; Brenda M Sandmaier; Paul V O'Donnell; Brian Phillips; Linda Risler; David K Blough; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2008-04-09       Impact factor: 3.333

10.  9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.

Authors:  L Danhauser; W Plunkett; M Keating; F Cabanillas
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more
  3 in total

Review 1.  Direct and indirect quantification of phosphate metabolites of nucleoside analogs in biological samples.

Authors:  Nagsen Gautam; Jawaher Abdullah Alamoudi; Sushil Kumar; Yazen Alnouti
Journal:  J Pharm Biomed Anal       Date:  2019-10-03       Impact factor: 3.935

2.  Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.

Authors:  Vijay Ivaturi; Christopher C Dvorak; Danna Chan; Tao Liu; Morton J Cowan; Justin Wahlstrom; Melisa Stricherz; Cathryn Jennissen; Paul J Orchard; Jakub Tolar; Sung-Yun Pai; Liusheng Huang; Francesca Aweeka; Janel Long-Boyle
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-03       Impact factor: 5.742

3.  Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability.

Authors:  Tashinga E Bapiro; Frances M Richards; Duncan I Jodrell
Journal:  Anal Chem       Date:  2016-06-08       Impact factor: 6.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.